The role of direct immunofluorescence and serologic immunologic assays for the diagnosis of autoimmune dermatose of the skin.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00009773

Enrollment

160

Registered

2016-03-31

Start date

2015-06-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune disease

Interventions

Group 1: Direct and indirect immunofluorescence of skin samples: IgG, IgA, IgM, IgE, C3 and fibrinogen in vitro staining of direct immunofluorescence and serologic tests (indirect immunofluorescence,

Eligibility

Sex/Gender

All

Age

0 Days to No maximum

Inclusion criteria

Inclusion criteria: - Patients treated at the Department of Dermatology / the Medical Center - University of Freiburg - Samples taken as part of medical treatment - In the process of diagnostic sampling patients consent to scientific use of material that is not needed for diagnostic testing.

Exclusion criteria

Exclusion criteria: No written informed consent of patient

Design outcomes

Primary

Measure	Time frame
Correlation of diagnostic in vitro staining and exemination (direct and indirect immunofluorescence, ELISA, Immunoblots) in clinical and histological diagnose and progress	—

Countries

Germany

Contacts

Public ContactDimitra Kiritsi

UNIVERSITÄTSKLINIKUM FREIBURGKlinik für Dermatologie und Venerologie

dimitra.kiritsi@uniklinik-freiburg.de0761 270-67010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026